<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672488</url>
  </required_header>
  <id_info>
    <org_study_id>METSOR</org_study_id>
    <nct_id>NCT02672488</nct_id>
  </id_info>
  <brief_title>Metformin Plus Sorafenib for Advanced HCC</brief_title>
  <official_title>Safety and Efficacy of Metformin Plus Sorafenib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma(BCLC-C): A Phase 2 Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metformin is a widely used oral drug for type 2 diabetes and its antitumor effects have got
      much more attentions recently. It has been shown that metformin exerts anti-cancer activities
      in several cancers, including primary liver cancer. In this phase II study, safety and
      efficacy of the combination of metformin and sorafenib will be evaluated in patients with
      advanced hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sorafenib is the standard choice for advanced hepatocellular carcinoma (BCLC-C), but the
      efficacy is not satisfied. Metformin is a widely used oral drug for type 2 diabetes and its
      antitumor effects have got much more attentions recently. It has been shown that metformin
      exerts anti-cancer activities in several cancers, including primary liver cancer. Recent
      studies suggest that metformin treatment can reduce the risk of HCC in patients with type 2
      diabetes and inhibit HCC invasion and increase drug sensitivity to sorafenib, however, the
      safety and efficacy of combined therapy for advanced hepatocellular carcinoma remains
      unclear. In this phase II study, patients with advanced hepatocellular carcinoma, measurable
      disease, and an Eastern Cooperative Oncology Group performance score≤1 will be enrolled.
      Eligible subjects will be randomly assigned to receive the treatment of sorafenib or
      metformin plus sorafenib. The potential improvement of overall survival, time to progression
      and safety will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months or time to death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time To Progression</measure>
    <time_frame>12 months or time to death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib and Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib 400μg tablet by mouth and Metformin 500mg tablet by mouth with meal, twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib 400μg tablet by mouth, twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Standard treatment for advanced HCC</description>
    <arm_group_label>Sorafenib and Metformin</arm_group_label>
    <arm_group_label>Sorafenib Alone</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC</description>
    <arm_group_label>Sorafenib and Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability of the research subject or authorized legal representative to understand and
             the willingness to sign a written informed consent document

          2. Confirmed hepatocellular carcinoma according to one of following three criteria:

             histopathology,Two radiographic techniques (US, MRI, CT, or Angiography) that confirm
             lesion with typical arterial hypervascularization,Barcelona Clinical Liver Cancer
             staging C (BCLC-C)

          3. Age &gt; 18 years old

          4. Patients with liver disease classified as Child Pugh class A

          5. Eastern Clinical Oncology Group (ECOG) performance status 0，1 or 2 (Appendix I)

          6. Hemoglobin ≥ 9 g/dL

          7. Absolute Neutrophil count（ANC）≥ 1,500 /mm3

          8. Platelet count≥ 50,000 /ul

          9. Total Bilirubin &lt; 2 mg/dL

         10. Transaminases (SGOT and SGPT) no more than 5 times the upper limit of normal

         11. Alkaline phosphatase &lt; 4 times the upper limit of normal

         12. Both men and women and members of all races and ethnic groups are eligible for this
             study

         13. Prothrombin time &gt; 50% 或 PT-INR &lt; 2.3

        Exclusion Criteria:

          1. Child Pugh Score is 7 with ascites

          2. Severe cardiovascular disease

          3. Uncontrollable hypertension

          4. History of HIV infection

          5. Active clinical severe infection（&gt;grade 2 ，NCI-CTCAE Version3.0）

          6. Women who are pregnant

          7. Administration of any systemic chemotherapy within the last 6 months

          8. Presence of History of gastrointestinal bleeding before randomization

          9. Epileptic seizures requiring drug therapy

         10. History of allograft transplantation

         11. Patients with signs of bleeding or medical history

         12. Patients undergoing kidney dialysis

         13. Metastatic liver cancer

         14. Uncontrollable ascites

         15. Encephalopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ti Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhao Yan, PhD</last_name>
    <phone>+862223340123</phone>
    <phone_ext>6012</phone_ext>
    <email>chengdongyan916@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dongyan Cheng, MS</last_name>
    <phone>+862223359984</phone>
    <email>chengdongyan916@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TI ZHANG, MD</last_name>
      <phone>+862223340123</phone>
      <phone_ext>3092</phone_ext>
      <email>zhangti@tjmuch.com</email>
    </contact>
    <contact_backup>
      <last_name>Huikai Li, MD</last_name>
      <phone>+862223340123</phone>
      <phone_ext>3091</phone_ext>
      <email>lihuikai@tjmuch.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

